cardiovascular disease have shown the use of genomic information in risk prediction.
Genetic variation in subjects with CHF may determine outcomes, 10, 11 but previous studies on the prognosis of HF and related GRS remain unclear. First, CHF has broad spectrum of aetiology and heterogeneity of symptoms 12 ; however, the common characteristics of genetics and/or environment have verified a final common pathway in CHF. 13 Second, the outcomes of HF have cumulative effects for multiple risk factors interaction. In determining the prognosis of CHF, the role of monogenic variant is rare, and this will miss the superposition of minor genetic variations.
Hence, there is a considerable room for improvement to genetic risk assessment for CHF.
Here, we reported a whole exome sequencing wide GRS for CHF to provide prognosis risk evaluation. We re-analysed the mass spectrometry (MS) data for 34 non-failing and failing human left ventricular myocardium. 14 Moreover, in more than three phenotypes of failing heart, such genes will be included only if it has the same variability trend as normal contrast expression (P < 0.05), and thus were detected from whole exome sequencing data of 1000 Han Chinese CHF patients (787 idiopathic dilated cardiomyopathy and 213 ischaemic dilated cardiomyopathy). GRS for HF was constructed utilizing cox regression in HF cohort, to evaluate the stratifying prognosis and risk performance of GRS in 1000 CHF study cohort.
| MATERIAL S AND ME THODS

| Data of mass spectrometry of human myocardial tissue
Thirty four hearts samples were all diagnosed and collected by Chen from the Hospital of the University of Pennsylvania. 14 The baseline of samples is available on https ://www.nature.com/ artic les/ s41591-018-0046-2#Sec33. Proteomic data of these patients can be publicly downloaded from proteomeXchange (http:// www.prote omexc hange.org/,PXD00 8934). The flow chart of the current study is provided in Figure S1 .
| Study subjects for whole exome sequencing
The Institutional Ethics Committee of Tongji Hospital approved this study, which followed the principles of the declaration of Helsinki. Meanwhile, β-blocker taking as an adjusted factor was collected in different time points. Inclusion and exclusion criteria and the details of data processing and quality control are provided in Appendix S1. 
| Whole exome sequencing and bioinformatics workflow
Genomic DNA was extracted from peripheral blood leukocytes 
| Data processing and quality control
The WES data were stored with Variant Call Format (VCF). The VCFtools (https ://github.com/vcfto ols/vcftools) was used to perform data analysis, and invalid data were eliminated before establishing available data pools. Considering the repeatability of data processing, we employed appropriate quality control procedures to suit the whole exome sequencing summary statistics adapted for minor allele frequency. PLINK 16 was used to control imputation quality and Hardy-Weinberg equilibrium. Genetic principal components (PCs) 17 was used for cohort structure quality control.
| Construction of GRS
A detailed description is offered in Appendix S1. Briefly, (a) we built a GRS based on mass spectrometry of human myocardial tissue and 19 were used for assessment of GRS.
| Statistical analysis
To test the association of HF susceptibility variants with the prognosis of CHF risk factors, we used a combination of linear and logistic regression adjusting for age at first visit, gender, SNPs and conventional risk factors. These analyses were based on additive models. We considered the significant of SNP risk factor association threshold of P < 0.05.
We analysed individual SNPs and tertiles of genetic risk score, which were adjusted using conditional logistic regression of GRS for age, gender and conventional risk factors, and the significance of the difference in the receiver operating characteristic (ROC) curves was tested with C-index approach. Linkage disequilibrium (LD) was calculated by Haploview version 4.1. Data are expressed as mean ± SEM of experiments. Volcano plots (differential expression of genes for construction of GRS) were plotted by the R package 'ggplot2.' Data analyses were performed using SPSS 24.0 (SPSS, Inc) for Windows (Microsoft Corp).
| RE SULTS
| Differential gene expression analysis
In the online file (PXD008934), 3764 genes per group were available for analysis, and we filtered meaningful genes of P < .05 per group. The above conditions were for genes that were in more than three groups for HCMpEF, HCMrEF, DCM and ICM. Using Venn diagram to analyse the overlapping gene ( Figure 1A) , ultimately, 319 genes were chosen (details seen in Table S1 ). Baseline data for these samples are listed in https ://www.nature.com/artic les/s41591-018-0046-2#Sec33 .
| Whole exome sequencing
Seventy seven thousand, two hundred and eighty seven variants of Minor Allele Frequency (MAF) > 0.05 were identified in the whole exome sequencing from 1000 CHF objects, with 45 125 LD-prune variants, which were used for the stratification of population ( Figure 1B ).
| Differential gene loci and prognosis of patients with heart failure
To confirm the association between genetic alterations of common genes in the MS of heart failure tissues and the prognosis of CHF patients, 441 SNPs harboured in differentially expressed genes (Table   S2) Table 2 , Table S7 ). The following genes AGT, SLC25A13, HRG, APOB, SOD3, SYNM and TLN2 were included in the GRS study. In addition, volcano plot was used to display the variance of candidate genes among the different types of failing hearts ( Figure 1C -F).
| Predictive effect of GRS on the prognosis of HF
For each individual, we calculated CHF-specific genetic scores using the weighted sum of the risk allele (zero, one, or two for risk alleles at each locus; Figure 2A ). These scores were weighted according to the size effect reported in the endpoints studies. Genetic risk score was strongly associated with the prognosis of CHF by univariable analysis (HR = 1.28, 95% CI 1.19-1.37, P = 5.16 × 10 −11 ) and multivariable analysis including adjusted traditional risk factors and β blocker taking (HR = 1.28, 95% CI 1.18-1.37, P = 2.19 × 10 −10 ) by Cox Proportional Hazard Analyses ( Table 3) . traditional risk factors 20 ) with details provided in Table S3 . The consistency of estimates for the models did not change when adjustment for traditional risk factors was compared with the original risk only.
Participants in the top tertiles of genetic risk score were estimated to have 3.56-times increased risk of primary outcomes compared with those in the bottom tertiles (95% CI 2.36-5.37, P = 1.34 × 10 −9 ).
After adjustment for age, gender and traditional risk factors, the HRs remained the same, with 3.68-times expansion (95% CI 2.40-5.65, P = 2.47 × 10 −10 ; Figure 2B , Table S4 ).
When the genetic risk score was divided into quartiles as previous tertiles, results were consistent and associated with the prognosis of CHF; details are provided in Table S3 . Figure 2C , Table S4 ).
To compare GRS predictive validity to traditional risk factor, we constructed a risk prediction model that included gender, age, hypertension, hyperlipemia, diabetes mellitus and current smoking. By employing binary logistical regression to analyse the traditional risk factors, a predictive indicator was taken for the receiver operating TA B L E 3 Results of univariable and multivariable cox proportional hazard analyses for cardiac events characteristic (ROC) curves. The N-terminal B-type natriuretic peptide (NT-proBNP) was built as a contrast scale, which has been widely recognized as an important prognostic indicator of heart failure. [21] [22] [23] NT-proBNP in GRS of tertiles and quartiles showed no differentiation with ANVOA (P = 0.895; P = 0.704; Table S8 ). In Cox regression of prognosis of CHF, models based on age had higher C-index (C = 0.626; 95% CI: 0.595-0.656) than any of the individual conventional risk factors, with the second-best model being GRS on assessment (C = 0.620; 95% CI: 0.589-0.650; Figure 3A Figure 3B and C, Tables S5 and S6 ).
| D ISCUSS I ON
Genetic counselling is recommended for CHF patients and their family members. 24 It has always been of clinical focus to foresee the risk of heart failure via genetic background characteristics. GRS was used to identify patients with Mendelian and complex disease 25 patterns known as loci for HF risk factors, such as CAD, Cardiometabolic Disease, 8, 26 Blood Pressure 9 and atrial fibrillation. 27 Heart failure has similar or worse prognosis when compared to most cancers. 28 Traditional risk factors 20 have been used in risk prediction. However, obtaining GRS to predict the prognosis of HF remains challenging.
Here, we made an effort to incorporate genetic risk scores into clinical practice for determining the outcome of CHF.
In analysing the data from case-control mass spectrometry of human left ventricle tissue in this cohort study, 441 genes were is an antioxidant enzyme that catalyses the conversion of superoxide radicals into hydrogen peroxide and oxygen, which may protect the heart from oxidative stress. 33 SYNM is an intermediate filament (IF) family member, which primarily functions as mechanical stress, maintains structural, and related to smooth muscle cell cytoskeleton of the heart, with its absence causing ventricular dysfunction in mice. 34 TLN2 belonging to the talin protein family is a cytoskeletal protein, which is highly expressed in cardiac muscle when loss of talin-1 and talin-2 leads to dilated cardiomyopathy and cardiac dysfunction in mice. 35 The following conclusions can be drawn from our findings. First, we reported a series of findings that attempted to stratify individuals with HF using genomic information prognosis in general populations, an approach that leverages the fixed nature of germline DNA over the life course to anticipate different lifelong trajectories of CHF. Second, the variants from case-control differentially expressed genes appeared to affect the outcomes, including those from whole exome sequencing prospective cohorts. Third, further adjustment for traditional risk factors had no effect on the risk estimates because of the genetic risk score. Finally, genetic risk score combined with traditional risk factors improved risk discrimination when assessed with the C-index (P = 0.017), and this is strongly associated with the outcomes of HF.
Overall, this is a challenge to any single risk factor to predict prognosis of CHF via complex traits. Our combined results showed much powerful risk discriminations between the tails of genetic risk scores. The differences cannot be accounted by NT-proBNP as they are similar for each score in our study. Hence, higher genetic risk indicating individuals that have more genetic risk alleles has worse prognosis even if they have the same level of NT-proBNP.
Subdividing patients can help us identify high-risk individuals more accurately. For clinical practice, providing precise interventions for variants subjects in early stage of CHF (stage A or B) would improve benefits. This potential value of using genetic risk score and optimizing the use of scarce resources for the estimation of the endpoint of CHF would be revalidated in further studies.
| Study limitations
First, the SNPs used for GRS panel construction should be enriched.
For example, more potential differential genes can be obtained after augmenting the sample size of MS control-case. Meanwhile, extensive whole exome sequencing cohort potential candidate variants will unfold with GRS. Second, there are racial differences between mass spectrometry (MS) samples and whole exome sequencing population. Another population or other ancestries are needed to verify the results. However, the potential clinical use of GRS can be predicted. Third, the expansion of the sample size of CHF population is needed, and future studies on large multiethnic cohorts will validate GRS. Fourth, other widely accepted heart failure prognostic risk scores, such as Seattle heart failure model should be included as control in subsequent studies. Fifth, we did not include the index of family history in traditional risk. The information about disease and its direct relations is often vague, which may be related to the level of medical care in the past.
| CON CLUS ION
We developed and assessed a genetic score based on eight SNPs in the current study, and we demonstrated that it was associated with the first event of heart failure endpoint. We attempted the concept of engaging genomic information to stratify individuals for CHF prognostic risk and to improve risk reclassification for participants, and we demonstrated a hypothesis to predict the outcomes of genomic screening to complement conventional risk and NT-proBNP.
